

CalciMedica Inc

Fact Sheet

CALC

LISTED

NASDAQ

CalciMedica

QUICK REFERENCE

CalciMedica Inc

Nasdaq: **CALC**

www.CALCIMEDICA.com

BUSINESS SUMMARY

CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica is currently conducting a Phase 2b trial for a planned 216 patients (called CARPO – NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), with topline data expected in the first half of 2024, as well as supporting the ongoing Phase 1/2 CRSPA asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA – NCT04195347), with additional data expected by 2H 2024. CalciMedica plans to initiate a Phase 2 study in acute kidney injury (AKI) in 1H 2024. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research.

TECHNOLOGIES & PIPELINE

Lead Candidate

Auxora™'s Dual Mode of Action: As a CRAC Channel Inhibitor, Auxora™ Modulates the Immune Response and Protects Against Tissue Cell Injury

- Preclinical and clinical data have demonstrated that the inhibition of CRAC channels may have a therapeutic effect based on a dual mechanism involving both anti-inflammatory and tissue cell protective activities.
- CalciMedica is developing Auxora™ as a potential disease-modifying therapy for patients with life-threatening inflammatory diseases of the pancreas, kidney and lung, for which there are currently no approved therapies.

Immune Cells: Modulates Immune Response

In immune cells, activation of CRAC channels is a key step in initiating the adaptive immune response and the generation of inflammatory signals such as cytokines. Inhibiting CRAC channels with Auxora™ may reduce immune cell activation and the accompanying inflammation driven by the immune response.

Non-Immune Cells: Blocks Calcium from Entering the Cells

CRAC channels on affected organ tissue cells can become inappropriately activated or overactivated, resulting in excess calcium entry into cells. This excess calcium can cause cellular injury and necrosis or activate apoptosis signaling pathways leading to programmed cell death, which is further exacerbated by the damage caused by the inflammatory response. Inhibiting CRAC channels with Auxora™ may reduce organ damage by blocking excess calcium.

CONTACT INFORMATION

Headquarters
505 Coast Boulevard South
La Jolla, CA 92037

Barwicki Investor Relations
Andrew Barwicki
516-662-9461 / andrew@barwicki.com

Recent Press Releases *(Headlines and Excerpts)*

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

- *Continued expansion of Phase 1/2 CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT); data from initial cohort to be presented at 65th Annual American Society of Hematology (ASH) Meeting & Exposition*
- *International expansion of Phase 2b CARPO trial in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS) continues; topline data expected in the first half of 2024*

Nov. 9, 2023 -- CalciMedica Inc. today reported financial results for the third quarter ended September 30, 2023.

Clinical and Pre-Clinical Updates and Anticipated Milestones:

- Collaborators at St. Jude Children's Research Hospital (SJCRH) have continued expansion of the Phase 1/2 CRSPA trial of Auxora™ in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT). Data from the initial cohort of the CRSPA study, including comparisons of data from CRSPA with matched historical control patients at SJCRH, will be presented by SJCRH investigators at the 65th Annual ASH Meeting & Exposition, being held December 9-12, 2023 in San Diego, CA.
- Data from the initial cohort of the CRSPA study compared with matched historical controls indicate that Auxora™ showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit days and eliminated the need for total parenteral nutrition (in contrast to an average 27 days of total parenteral nutrition for the matched historical control group).
- CalciMedica's clinical investigators are continuing to enroll patients in CARPO, CalciMedica's Phase 2b clinical trial of Auxora™ in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS), including in India, following the international expansion of the study there. CalciMedica anticipates that topline data from the CARPO trial will be available in the first half of 2024.
- CalciMedica is preparing to file an IND application for Auxora™ in acute kidney injury (AKI). If allowed, CalciMedica expects it will be in a position to initiate a Phase 2 clinical trial in AKI in the first half of 2024, subject to receipt of additional funding.

Financial Results for the Three and Nine Months Ended September 30, 2023:

- As of September 30, 2023, CalciMedica had \$14.6 million in cash, cash equivalents and short-term investments, which, based on its current operating plan, CalciMedica expects to be sufficient to fund its operations through the third quarter of 2024.
- Total operating expenses were \$4.8 million for the three months ended September 30, 2023. Total operating expenses were \$33.8 million for the nine months ended September 30, 2023, which included \$16.2 million of one-time charges of which \$10.5 million was non-cash, related to accelerated vesting of stock options and severance for employees of Graybug Vision, Inc. at the time of the reverse merger with Graybug. The majority of costs stemming from the reverse merger have been expensed.
- Net loss was \$4.6 million, or \$0.82 per share (basic and diluted), and \$30.2 million, or \$7.43 per share (basic and diluted), for the three and nine months ended September 30, 2023, respectively.

Corporate Updates

- In September 2023, CalciMedica hosted a virtual Acute Pancreatitis Clinical Experts Event featuring Joseph Miller, M.D., Clinical Associate Professor of Emergency Medicine at Henry Ford Health and Michigan State University and Associate Director of Emergency Care Research at Henry Ford Health, and Georgios Papachristou, M.D., Ph.D., Professor of Medicine, Floyd Beman Endowed Chair in Gastroenterology and division director for Gastroenterology, Hepatology and Nutrition at The Ohio State University College of Medicine. Management and the clinical experts discussed current treatment paradigms for AP and the potential implications of CalciMedica's lead clinical compound, Auxora™.

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

- *Auxora™ showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit (ICU) days and eliminated the need for total parenteral nutrition (TPN)*

Nov. 2, 2023 /PRNewswire/ -- CalciMedica Inc. announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora™ (zegoctractin) in asparaginase-induced pancreatic toxicity (AIPT) in a poster presentation at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition being held December 9-12, 2023 in San Diego, CA.

This Company Fact Sheet is distributed by Andrew Barwicki, Investor Relations. Contact Info: 516-662-9461 / andrew@barwicki.com
The information contained is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned. This Company Fact Sheet is an information publication and is considered investor relations & financial public relations material. All information is compiled from SEC Filings (U.S. Securities and Exchange Commission), press releases, conference calls, shareholder meetings, investment conferences, analyst reports, internet, company website and/or senior management interviews. This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

CalciMedica

Nasdaq: CALC

www.CALCIMEDICA.com

Deliver to: